|
| 37161516 | Apolipoprotein C-II: a new look at an old protein. | | 2023 |
| 37586912 | Variability of longitudinal triglyceride phenotype in patients heterozygous for pathogenic APOA5 variants. | | 2023 |
| 37813751 | Illuminating the full spectrum of APOE variation. | | 2023 |
| 37729501 | Comment on Huh et al. Remnant Cholesterol Is an Independent Predictor of Type 2 Diabetes: A Nationwide Population-Based Cohort Study. Diabetes Care 2023;46:305-312. | | 2023 |
| 37640407 | Apolipoprotein B in cardiovascular risk assessment. | | 2023 |
| 37638490 | Recommendations for statin management in primary prevention: disparities among international risk scores. | | 2023 |
| 37562541 | New Biological Therapies for Low-Density Lipoprotein Cholesterol. | | 2023 |
| 37626170 | RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts. | Nat Med | 2023 |
| 38061374 | New clarity for managing statin intolerance in diabetes. | | 2023 |
| 37217627 | Genetic testing in monogenic early-onset atrial fibrillation. | | 2023 |
| 37089071 | Low cholesterol states: clinical implications and management. | | 2023 |
| 37088965 | First reports of primary ciliary dyskinesia caused by a shared DNAH11 allele in Canadian Inuit. | Pediatr Pulmonol | 2023 |
| 37212306 | Statin associated muscle symptoms (SAMS): strategies for prevention, assessment and management. | | 2023 |
| 37272523 | Rare neurovascular genetic and imaging markers across neurodegenerative diseases. | Alzheimers Dement | 2023 |
| 36960729 | Genetic Identification of Homozygous Familial Hypercholesterolemia by Long-Read Sequencing Among Patients With Clinically Diagnosed Heterozygous Familial Hypercholesterolemia. | | 2023 |
| 36641373 | The advantages and pitfalls of genetic analysis in the diagnosis and management of lipid disorders. | | 2023 |
| 37259864 | Academic-Industry Partnerships: Transparency, Potential Conflict of Interest, and Communicating State-of-the-Art Technologies. | | 2023 |
| 36752614 | Genetic determinants of pancreatitis: relevance in severe hypertriglyceridemia. | | 2023 |
| 36700190 | The Impact of Low-Density Lipoprotein Equation Changes on Cholesterol Treatment in Canada. | | 2023 |
| 37322181 | International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia. | Nat Rev Cardiol | 2023 |
| 37130090 | 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. | | 2023 |
| 37003850 | Metabolic syndrome predicts cardiovascular risk and mortality in familial hypercholesterolemia. | | 2023 |
| 36476373 | The longitudinal triglyceride phenotype in heterozygotes with LPL pathogenic variants. | | 2023 |
| 37377517 | Awareness Among Primary Care Physicians in Canada of Guideline Recommendations for Lowering LDL-Cholesterol in High-Risk Patients. | | 2023 |
| 37305647 | Treatment of Homozygous Familial Hypercholesterolemia With ANGPTL3 Inhibitor, Evinacumab. | | 2023 |
| 37114828 | Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-III inhibitors. | | 2023 |
| 36689289 | Genetic Variants Associated with Severe Hypertriglyceridemia: LPL, APOC2, APOA5, GPIHBP1, LMF1, and APOE. | | 2023 |
| 36734990 | How reliable are polygenic risk scores for risk prediction in patients with heart disease? | | 2023 |
| 36682941 | Genetic testing in dyslipidaemia: An approach based on clinical experience. | | 2023 |
| 37105239 | LDL-C Estimation Equation Performance Characteristics Highlight Value of Preferentially Using Non-HDL Cholesterol or Directly Measured Apolipoprotein B. | | 2023 |
| 36853833 | DNA testing in dyslipidemia: attitudes and complexities. | | 2023 |
| 37101608 | Cost-Effectiveness of Icosapent Ethyl (IPE) for the Reduction of the Risk of Ischemic Cardiovascular Events in Canada. | | 2023 |
| 36529464 | 'Keep on keeping on': persistence with lipid-lowering treatment in familial hypercholesterolaemia. | | 2023 |
| 37529775 | Editorial: Rare dyslipidemias. | | 2023 |
| 37545679 | ABCA1 Deficiency: A Rare Cause of Premature Coronary Artery Disease. | | 2023 |
| 34690300 | Familial combined hyperlipidemia is a polygenic trait. | Current Opinion in Lipidology | 2022 |
| 36047048 | Effect of the LDL receptor mutation type on incident major adverse cardiovascular events in familial hypercholesterolaemia. | European Journal of Preventive Cardiology | 2022 |
| 35772917 | LMNA Variants and Risk of Adult-Onset Cardiac Disease. | J Am Coll Cardiol | 2022 |
| 36243606 | Guidance for the diagnosis and treatment of hypolipidemia disorders. | Journal of Clinical Lipidology | 2022 |
| 35521712 | Hypertriglyceridemia in young adults with a 22q11.2 microdeletion. | Eur J Endocrinol | 2022 |
| 36229375 | A mechanism-based operational definition and classification of hypercholesterolemia. | Journal of Clinical Lipidology | 2022 |
| 35961755 | The Detection, Evaluation, and Management of Dyslipidemia in Children and Adolescents: A Canadian Cardiovascular Society/Canadian Pediatric Cardiology Association Clinical Practice Update. | Canadian Journal of Cardiology | 2022 |
| 35762447 | Safety and efficacy of therapies for chylomicronemia. | Expert Review of Clinical Pharmacology | 2022 |
| 35386132 | Treatment of Homozygous Familial Hypercholesterolemia With Evinacumab. | CJC Open | 2022 |
| 35386091 | Monogenic Versus Polygenic Forms of Hypercholesterolemia and Cardiovascular Risk: Are There Any Differences? | Current Atherosclerosis Reports | 2022 |
| 35953141 | Lipoprotein(a) and Atrial Fibrillation. | Journal of the American College of Cardiology | 2022 |
| 35636639 | Defective KIM-1 phagocytosis does not predispose to acute graft dysfunction after kidney transplantation in humans. | Kidney Int | 2022 |
| 36216435 | Physiological Bases for the Superiority of Apolipoprotein B Over Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk. | Journal of the American Heart Association | 2022 |
| 35495867 | Is Deprescription of Ezetimibe Safe in Familial Hypercholesterolemia Patients Taking Evolocumab? | CJC Open | 2022 |
| 36075245 | PCSK9 inhibition in children with familial hypercholesterolaemia. | Lancet Diabetes and Endocrinology,The | 2022 |